IP Library Granted Patent US 9,155,815
Granted Patent B2
US 9,155,815 · App. 12/757,432 · Granted Oct 13, 2015

Biocompatible phase invertible proteinaceous compositions and methods for making and using the same

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,155,815
App. No.
12/757,432
Granted
Oct 13, 2015
Kind
B2
Abstract

Biocompatible phase invertible proteinaceous compositions and methods for making and using the same are provided. The subject phase invertible compositions are prepared by combining a crosslinker and a proteinaceous substrate. The proteinaceous substrate includes one or more proteins and a polyamine, where the polyamine and a proteinaceous substrate are present in synergistic viscosity enhancing amounts, and may also include one or more of: a carbohydrate, a tackifying agent, a plasticizer, or other modification agent. In certain embodiments, the crosslinker is a heat-treated dialdehyde, e.g., heat-treated glutaraldehyde. Also provided are kits for use in preparing the subject compositions. The subject compositions, kits and systems find use in a variety of different applications.

Claims (37)

1. A phase invertible composition produced by combining:

a substrate comprising a polyamine and a proteinaceous material in a weight ratio having a synergistic viscosity enhancing effect, wherein the combination of the polyamine and the proteinaceous material has a viscosity which is greater than that of either the polyamine or the proteinaceous material alone; and

a crosslinking agent, wherein the crosslinking agent causes the polyamine and the proteinaceous material to crosslink and the polyamine and the proteinaceous material crosslink in the presence of the crosslinking agent,

wherein said substrate has a kinematic viscosity of about 70 to 200 centistokes,

wherein said proteinaceous material is selected from the group consisting of albumin, elastin, fibrin and soluble and insoluble forms of collagen and combinations thereof, and

wherein the crosslinking agent comprises a macromolecular crosslinking agent comprising a reaction product of an excess of a liquid aldehyde cross linking agent and a glycosaminoglycan.

2. The phase invertible composition according to claim 1 , wherein said polyamine is a polyalkyienimine.

3. The phase invertible composition according to claim 2 , wherein said polyalkyenimine is a polyethylenimine.

4. The phase invertible composition according to claim 3 , wherein said polyethylenimine is a branched polyethylenimine.

5. The phase invertible composition according to claim 4 , wherein the weight ratio of branched polyethylenimine to proteinaceous material is about 1:5 to 80.

6. The phase invertible composition according to claim 5 , wherein the weight ratio of branched polyethylenimine to proteinaceous material is about 1:10 to 40.

7. The phase invertible composition according to claim 1 , wherein said substrate further comprises a carbohydrate.

8. The phase invertible composition according to claim 7 , wherein said carbohydrate is chitosan.

9. The phase invertible composition according to claim 1 , wherein said crosslinking agent comprises an aldehyde.

10. The phase invertible composition according to claim 9 , wherein said aldehyde is glutaraldehyde.

11. The phase invertible composition according to claim 10 , wherein said glutaraldehyde is heat stabilized.

12. The phase invertible composition according to claim 1 , wherein said glycosaminoglycan is hyaluronan.

13. The phase invertible composition according to claim 1 , wherein the viscosity of said substrate approximates that of said crosslinking agent.

14. The phase invertible composition according to claim 13 , wherein said crosslinking agent further comprises a viscosity modifying agent.

15. The phase invertible composition according to claim 1 , wherein said substrate further comprises an agent selected from the group consisting of a tackifying agent, and a plasticizing agent.

16. The phase invertible composition according to claim 1 , wherein said crosslinking agent further comprises an agent selected from the group consisting of a tackifying agent, and a plasticizing agent.

17. A method for treating a host, said method comprising delivering the composition of claim 1 to a target location.

18. A method of producing a phase invertible composition, said method comprising:

combining:

(a) a liquid substrate comprising a polyamine and a proteinaceous material in a weight ratio having a synergistic viscosity enhancing effect, the weight ratio of polyamine to proteinaceous material being about 1:4 to 1:400, wherein the combination of the polyamine and the proteinaceous material has a viscosity which is greater than that of either the polyamine or the proteinaceous material alone; and

(b) a liquid crosslinking agent to cause the polyamine and the proteinaceous material to crosslink to produce said phase invertible composition, wherein the polyamine and the proteinaceous material crosslink in the presence of the crosslinking agent,

wherein said substrate has a kinematic viscosity of about 70 to 200 centistokes,

wherein said proteinaceous material is selected from the group consisting of albumin, elastin, fibrin and soluble and insoluble forms of collagen and combinations thereof and

wherein the crosslinking agent comprises a macromolecular crosslinking agent comprising a reaction product of an excess of a liquid aldehyde cross linking agent and a glycosaminoglycan.

19. A solid phase composition produced by the method of claim 18 .

20. A kit for producing a phase invertible composition, said kit comprising:

(c) a substrate comprising a polyamine and a proteinaceous material in a weight ratio which produces a synergistic viscosity enhancing effect when combined, the weight ratio of polyamine to proteinaceous material being in the range from 1:5 to 1:100, wherein the combination of the polyamine and the proteinaceous material has a viscosity which is greater than that of either the polyamine or the proteinaceous material alone; and

a crosslinking agent composition comprising a crosslinking agent, wherein the crosslinking agent causes the polyamine and the proteinaceous material to crosslink and the polyamine and the proteinaceous material crosslink in the presence of the crosslinking agent,

wherein said substrate has a kinematic viscosity of about 70 to 200 centistokes,

wherein said proteinaceous material is selected from the group consisting of albumin, elastin, fibrin and soluble and insoluble forms of collagen and combinations thereof and

wherein the crosslinking agent comprises a macromolecular crosslinking agent comprising a reaction product of an excess of a liquid aldehyde cross linking agent and a glycosaminoglycan.

21. The kit according to claim 20 , wherein said kit further comprises a phase invertible fluid delivery device.

Assignments (5)
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 043596, FRAME 0259 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; THERAKOS, INC.; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065610/0324 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 12, 2018
From: MALLINCKRODT PHARMA IP TRADING DAC
To: BAXTER INTERNATIONAL, INC.
Reel/Frame 046051/0900 →
NUNC PRO TUNC ASSIGNMENT Recorded Oct 3, 2017
From: TENAXIS MEDICAL, INC.
To: MALLINCKRODT PHARMA IP TRADING D.A.C.
Reel/Frame 043767/0923 →
NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS Recorded Aug 18, 2017
From: MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY
To: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
Reel/Frame 043596/0259 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 28, 2010
From: HANDLEY, IAN; WONG, JOANNA
To: TENAXIS MEDICAL, INC.
Reel/Frame 024459/0251 →